

Updates on COVID-19 in Republic of Korea

10 May 2021

COVID-19 vaccination status as of 0:00 today (cumulative since 26 February 2021) (n, %)

| | Total | City | | | | | | | | | | |
|------------------|------------------------------|-----------|---------|---------|---------|---------|---------|--------|--------|--|--|--|
| | iotai | Seoul | Busan | Daegu | Incheon | Gwangju | Daejeon | Ulsan | Sejong | | | |
| Eligible | 6,347,957 | 1,113,747 | 453,065 | 291,807 | 315,713 | 178,524 | 169,853 | 99,737 | 26,802 | | | |
| New (1st dose) | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | |
| New (2nd dose) | 4,734 | 0 | 0 | 1,028 | 0 | 0 | 0 | 0 | 0 | | | |
| Total (1st dose) | 3,674,729 | 591,041 | 230,607 | 156,962 | 181,511 | 116,508 | 104,444 | 61,752 | 18,448 | | | |
| Total (2nd dose) | e) 506,274 73,295 23, | | 23,995 | 20,224 | 30,551 | 14,748 | 12,119 | 12,760 | 4,697 | | | |
| % (1st dose) | 57.9 | 53.1 | 50.9 | 53.8 | 57.5 | 65.3 | 61.5 | 61.9 | 68.8 | | | |
| % (2nd dose) | 8.0 | 6.6 | 5.3 | 6.9 | 9.7 | 8.3 | 7.1 | 12.8 | 17.5 | | | |

| | | Province | | | | | | | | | | | |
|------------------|-----------|----------|---------------|---------------|--------------|--------------|----------------|----------------|--------|--|--|--|--|
| | Gyeonggi | Gangwon | Chung- buk | Chung- nam | Jeon- buk | Jeon- nam | Gyeong- buk | Gyeong- nam | Jeju | | | | |
| Eligible | 1,348,610 | 253,698 | 222,076 | 310,208 | 301,015 | 337,087 | 413,664 | 430,337 | 82,014 | | | | |
| New (1st dose) | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | | | | |
| New (2nd dose) | 1,288 | 0 | 0 | 777 | 0 | 0 | 1,641 | 0 | 0 | | | | |
| Total (1st dose) | 803,371 | 147,692 | 135,758 | 178,965 | 186,313 | 218,748 | 235,192 | 261,678 | 45,739 | | | | |
| Total (2nd dose) | 94,355 | 26,339 | 25,395 | 26,959 | 26,054 | 31,900 | 35,897 | 36,801 | 10,185 | | | | |
| % (1st dose) | 59.6 | 58.2 | 61.1 | 57.7 | 61.9 | 64.9 | 56.9 | 60.8 | 55.8 | | | | |
| % (2nd dose) | 7.0 | 10.4 | 11.4 | 8.7 | 8.7 | 9.5 | 8.7 | 8.6 | 12.4 | | | | |

^{*} Figures subject to correction recording update

Adverse events following COVID-19 vaccination reported as of 0:00 today (cumulative since 26 February 2021)

| | | Vaccinated | (a) | (h) | Serious AEFI ^(c) | | | | | |
|--------------|-------|--------------|---------------------------|-----------------------------|-----------------------------|---------------------------|------------------------------------|-------------------------|--|--|
| | | (cumulative) | Total AEFI ^(a) | General AEFI ^(b) | Subtotal | Death ^① | Anaphylaxis suspected ² | Major AEFI [®] | | |
| Total | New | 4,181,003 | 80 | 75 | 5 | 0 | 0 | 5 | | |
| Total | Total | 4,101,003 | 19,705 | 18,987 | 718 | 95 | 187 | 436 | | |
| A -4 7 | New | 2,014,788 | 39 | 37 | 2 | 0 | 0 | 2 | | |
| AstraZeneca- | Total | 2,014,700 | 16,421 | 15,941 | 480 | 51 | 149 | 280 | | |
| DC. | New | 2,166,215 | 41 | 38 | 3 | 0 | 0 | 3 | | |
| Pfizer | Total | 2,100,213 | 3,284 | 3,046 | 238 | 44 | 38 | 156 | | |

- (a) Cases reported by healthcare institutions as suspected AEFI cases; does not indicate causal association
- (b) Common symptoms following vaccination including redness, pain, swelling, muscle pain, fever, headache, chills, etc.
- (c) Serious AEFI includes the following:
 - ① Death,
 - 2 Anaphalyxis suspected (including anaphylactoid reactions)
 - 3 Major AEFI: Adverse events of special interest (AESI), admission to ICU, critical condition, permanent disability/sequelae/etc.



Updates on COVID-19 in Republic of Korea

10 May 2021

Confirmed cases by gender and age group

| | | New cases | (%) | Total cases | (%) | Incidence rate* |
|-------|-------------|------------------|---------|-------------|---------|-----------------|
| | | 11ctv cases (70) | | Total cases | (70) | (per 100,000) |
| Total | | 463 | (100) | 127,772 | (100) | 246.44 |
| Cov | Male | 236 | (50.97) | 63,668 | (49.83) | 246.18 |
| Sex | Female | 227 | (49.03) | 64,104 | (50.17) | 246.70 |
| | 80 or above | 8 | (1.73) | 5,491 | (4.30) | 289.12 |
| | 70-79 | 35 | (7.56) | 9,156 | (7.17) | 253.83 |
| | 60-69 | 75 | (16.20) | 19,604 | (15.34) | 309.00 |
| | 50-59 | 69 | (14.90) | 23,637 | (18.50) | 272.73 |
| Age | 40-49 | 72 | (15.55) | 18,985 | (14.86) | 226.30 |
| | 30-39 | 64 | (13.82) | 17,304 | (13.54) | 245.62 |
| | 20-29 | 71 | (15.33) | 19,009 | (14.88) | 279.28 |
| | 10-19 | 53 | (11.45) | 9,009 | (7.05) | 182.35 |
| | 0-9 | 16 | (3.46) | 5,577 | (4.36) | 134.43 |

^{*} Total (cumulative) number of cases reported since January 2020 by sex and age / Population by sex and age (based on resident registration data of the Ministry of the Interior as of January 2020)

** Figures subject to correction based on findings from epidemiological investigations

Deaths and severe/critical patients by gender and age group

| | | New | (%) | Total | (%) | Case fatality | Severe/ | (%) | |
|-------|-------------|--------|--------|--------|---------|---------------|----------|---------|--|
| | | deaths | (%) | deaths | (%) | rate (%) | critical | (70) | |
| Total | | 1 | (100) | 1,875 | (100) | 1.47 | 161 | (100) | |
| Sex | Male | 0 | (0.00) | 933 | (49.76) | 1.47 | 90 | (55.90) | |
| Sex | Female | 1 | (100) | 942 | (50.24) | 1.47 | 71 | (44.10) | |
| | 80 or above | 1 | (100) | 1,035 | (55.20) | 18.85 | 38 | (23.60) | |
| | 70-79 | 0 | (0.00) | 531 | (28.32) | 5.80 | 65 | (40.37) | |
| | 60-69 | 0 | (0.00) | 220 | (11.73) | 1.12 | 30 | (18.63) | |
| | 50-59 | 0 | (0.00) | 65 | (3.47) | 0.27 | 18 | (11.18) | |
| Age | 40-49 | 0 | (0.00) | 14 | (0.75) | 0.07 | 8 | (4.97) | |
| | 30-39 | 0 | (0.00) | 7 | (0.37) | 0.04 | 2 | (1.24) | |
| | 20-29 | 0 | (0.00) | 3 | (0.16) | 0.02 | 0 | (0.63) | |
| | 10-19 | 0 | (0.00) | 0 | (0.00) | 0.00 | 0 | (0.00) | |
| | 0-9 | 0 | (0.00) | 0 | (0.00) | 0.00 | 0 | (0.00) | |

^{*} Case fatality rate (CFR) (%) = Number of deaths / Number of confirmed cases x 100 ** Figures subject to correction based on findings from epidemiological investigations

| AGE DISTRIBUTION OF SEVERE/CRITICAL CASES | | | | | | | | | | | | | | |
|---|-------|-------|-------|-------|-----|------|------|------|------|------|------|------|------|-------|
| | 4.27. | 4.28. | 4.29. | 4.30. | 5.1 | 5.2. | 5.3. | 5.4. | 5.5. | 5.6. | 5.7. | 5.8. | 5.9. | 5.10. |
| Total | 156 | 160 | 157 | 164 | 174 | 170 | 164 | 162 | 173 | 172 | 162 | 165 | 160 | 161 |

^{*} Severe/Critical: COVID-19 patients in isolation being treated with high flow oxygen therapy, mechanical ventilator, ECMO (Extracorporeal Membrane Oxygenation), CRRT (Continuous Renal Replacement Therapy)